INDP

Indaptus Therapeutics, Inc. (INDP) - Q2 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2025. Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company developing Decoy20, a novel immunotherapy for unresectable or metastatic solid tumors and lymphomas. The company is currently conducting a Phase 1 clinical trial for Decoy20 and a combination study with Tislelizumab. On June 26, 2025, the company effected a 1-for-28 reverse stock split to regain compliance with Nasdaq listing requirements; all share data in this filing is retroactively adjusted.

Key Financial Metrics

Note: The company has no revenue. The increase in net loss for YTD 2025 includes a non-cash charge of $0.79 million related to the change in fair value of convertible promissory notes.

Material Changes vs. Prior Period

• Financing Activity: In June 2025, the company raised approximately $5.7 million in gross proceeds via convertible promissory notes. These notes automatically converted into common stock and pre-funded warrants on July 27, 2025 (subsequent to the reporting period).
• Capital Structure: The company executed a 1-for-28 reverse stock split in June 2025. Outstanding shares decreased from ~16.9 million to ~605,000.
• Expense Trends: Research and Development (R&D) expenses increased by 50.6% YTD compared to 2024, driven by higher clinical trial costs for the Phase 1 study. General and Administrative (G&A) expenses decreased by 14.7% YTD, primarily due to reduced stock-based compensation and payroll, partially offset by transaction costs from the June financing.
• Liquidity: Cash balances decreased slightly from $5.79 million at year-end 2024 to $6.16 million at June 30, 2025, despite significant operating cash burn, due to net financing inflows of $9.4 million YTD.

Guidance, Outlook, and Risks

• Going Concern: Management has identified conditions raising substantial doubt regarding the company's ability to continue as a going concern. The company expects to fund operations into the fourth quarter of 2025 based on current cash and the Standby Equity Purchase Agreement (SEPA).
• Capital Needs: The company will require additional capital to fund clinical trials and operations. It has a SEPA allowing for up to $20 million in equity sales over 36 months; $1.75 million was raised under this agreement in the first half of 2025.
• Clinical Progress: The Phase 1 trial for Decoy20 has enrolled 13 participants for single-dose and 32 for weekly dosing. Enrollment in weekly dosing concluded in May 2025 to focus on the combination study with Tislelizumab. As of August 2025, 6 participants were enrolled in the combination study.
• Cost Reduction: In May 2025, the company implemented a cost-reduction plan, including voluntary salary reductions for officers and temporary elimination of board fees.
• Risks: Key risks include the inability to raise additional capital, clinical trial delays or failures, and the potential for dilution from future equity issuances.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $6.16 million cash balance to fund operations through Q4 2025, considering the high burn rate (~$9 million operating cash outflow YTD).
• Convertible Note Conversion: Confirm the final terms and dilution impact of the $5.7 million convertible notes that converted to equity in July 2025 (post-period).
• SEPA Utilization: Monitor the remaining capacity under the $20 million Standby Equity Purchase Agreement and the pricing terms for future draws.
• Clinical Milestones: Track safety data and dose recommendations from the Decoy20 Phase 1 trial and the combination study with Tislelizumab.
• Going Concern Status: Assess the likelihood of securing additional financing before the projected cash runway expires in late 2025.